A carregar...
克唑替尼治疗晚期或复发性ALK阳性非小细胞肺癌的疗效和安全性
BACKGROUND AND OBJECTIVE: Anaplastic lymphoma kinase (ALK) positive in non-small cell lung cancer (NSCLC) was about 5%-7% and ALK tyrosine kinase inhibitor (TKI) was the standard treatment in NSCLC. The aim of this study is to evaluate the efficacy and safety of crizotinib in patients with advanced...
Na minha lista:
| Publicado no: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
中国肺癌杂志编辑部
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6717874/ https://ncbi.nlm.nih.gov/pubmed/31451138 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2019.08.02 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|